Overview Submission Instructions Recent Publications Frequently Asked Questions Research Topics

Looking to publish in Current Hematologic Malignancy Reports? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now

Current Hematologic Malignancy Reports

Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on significant developments in hematologic malignancy. The journal emphasizes clear, balanced reviews of recently published papers and covers current and emerging approaches to diagnosis, treatment, management, and prevention. It is an online-only journal.

Looking to publish in Current Hematologic Malignancy Reports? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now

Subject Hematology, Oncology

Impact Factor 3.3

Quartile Q2

Open Access Type Hybrid

ISSN 1558-8211

eISSN 1558-822X

Invitation Only Yes

Cost Range Open access APC: £2690.00 GBP / $3990.00 USD / €3090.00 EUR; subscription publishing: no APC.

Submission Instructions

Current Hematologic Malignancy Reports is an invitation-only journal. Submissions are accepted by invitation from the editorial board only. The following article types are accepted:

Review

Cover Letter Cover Letter requirements are not specified.

Abstract An abstract is required. Abstract must be 150 to 250 words.

Manuscript Review articles must include a disclosure statement, 4 to 6 keywords, a Declarations section before the reference list, and documentation of any Large Language Model use in the Methods section or another suitable section if no Methods section is available.

References Citations must use numbered references in square brackets. The reference list must include only cited published or accepted works, be numbered consecutively, include full DOI links when available, and use standard journal title abbreviations or the full journal title if unsure.

Figures & Tables Figures should be submitted within the body of the text, with large figures submitted separately only if file size causes upload problems. Figures and tables must be numbered with Arabic numerals, cited in consecutive numerical order, and accompanied by captions, with figure captions included in the manuscript text file rather than in the figure file.

Reformat to Current Hematologic Malignancy Reports using Livewrite Premium

Invited Commentaries

Cover Letter Cover Letter requirements are not specified.

Abstract Abstract of 150 to 250 words is required. Abstract must be 150 to 250 words.

Manuscript Manuscript must include 4 to 6 keywords, a Declarations section before the reference list, documentation of any Large Language Model use in the Methods section or a suitable alternative section, and may require a disclosure statement depending on the commentary content.

References Citations must use numerical references in square brackets. Reference entries must be numbered consecutively, include only works cited in the text that are published or accepted for publication, and Invited Commentaries must cite appropriate and relevant literature supporting their claims.

Figures & Tables Figures should be submitted within the body of the text, with large figures submitted separately only if file size causes upload problems. Figures and tables must be numbered with Arabic numerals, cited in consecutive numerical order, and accompanied by concise captions, with figure captions included in the manuscript text file rather than the figure files.

Reformat to Current Hematologic Malignancy Reports using Livewrite Premium

Recent Publications

Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review

Kathryn E. Flynn, Lovneet Saini, Aditi Kataria, Kejal Jadhav, Daisy Yang, David Wei

10.1007/s11899-025-00755-0

View Publication

Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications

Nickolas Steinauer, Mrinal M. Patnaik

10.1007/s11899-025-00763-0

View Publication

Myelodysplastic syndromes: Updates on Genomic Landscape, Molecular Subtypes, & Targeted Therapies

Shirley S. Mo, Amy E. DeZern

10.1007/s11899-025-00762-1

View Publication

From MRD To Match: the Role of Allogeneic Hematopoietic Cell Transplant in Philadelphia-Negative B-ALL

Jessica El-Asmar, John C. Molina, Betty Ky Hamilton

10.1007/s11899-025-00760-3

View Publication

Plasmacytoid Dendritic Cell-Expansion in Acute Myeloid Leukemia (pDC‑AML): a Review of Clinicopathologic Features, Genetics, and Outcomes

Azza E. A. Abdalla, Mohammed Abdulgayoom, Abdulrahman F. Al-Mashdali, Firyal Ibrahim, Naseema Gangat, Shehab F. Mohamed

10.1007/s11899-025-00761-2

View Publication

Frequently asked questions

How long does it take to publish?

Articles are published online after receipt of the corrected proofs.

Reformat to Current Hematologic Malignancy Reports using Livewrite Premium

Is a cover letter required?

A submission letter is mentioned for reviewer suggestions and verification details.

Reformat to Current Hematologic Malignancy Reports using Livewrite Premium

What are the publication costs?

Open access APC: £2690.00 GBP / $3990.00 USD / €3090.00 EUR. Subscription publishing has no APC.

Reformat to Current Hematologic Malignancy Reports using Livewrite Premium

Research Topics

Acute Myeloid Leukemia Research Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Lymphoblastic Leukemia research CAR-T cell therapy research Eosinophilic Disorders and Syndromes Multiple Myeloma Research and Treatments Hematopoietic Stem Cell Transplantation Viral-associated cancers and disorders Childhood Cancer Survivors' Quality of Life Protein Degradation and Inhibitors CNS Lymphoma Diagnosis and Treatment Kruppel-like factors research Cutaneous lymphoproliferative disorders research Immune Cell Function and Interaction T-cell and Retrovirus Studies Immunodeficiency and Autoimmune Disorders Histone Deacetylase Inhibitors Research Peptidase Inhibition and Analysis Lung Cancer Treatments and Mutations Monoclonal and Polyclonal Antibodies Research Cancer Genomics and Diagnostics Virus-based gene therapy research

Related Journals

Journal of Urban Health Springer Science+Business Media

Calcified Tissue International Springer Science+Business Media

Lung Springer Science+Business Media

Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin Springer Science+Business Media

Liver Cancer Karger Publishers

BioDrugs Adis, Springer Healthcare